Expanding the Toolbox for Reversal of Anticoagulation in Chronic Kidney Disease

Affiliations

¹ Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, California. Electronic address: Khedraki.Rola@scrippshealth.org.
² Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, California; Scripps Research Translational Institute, La Jolla, California. Electronic address: https://twitter.com/EvanMuse.
³ Scripps Research Translational Institute, La Jolla, California.

Free article

Editorial

Rola Khedraki et al. J Am Coll Cardiol. 2019.

Free article

. 2019 Oct 8;74(14):1769-1771.

doi: 10.1016/j.jacc.2019.07.073.

¹ Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, California. Electronic address: Khedraki.Rola@scrippshealth.org.
² Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, California; Scripps Research Translational Institute, La Jolla, California. Electronic address: https://twitter.com/EvanMuse.
³ Scripps Research Translational Institute, La Jolla, California.

No abstract available

Keywords: anticoagulation; bleeding; dabigatran; idarucizumab; kidney disease; surgery.

Comment on

Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment.
Eikelboom JW, van Ryn J, Reilly P, Hylek EM, Elsaesser A, Glund S, Pollack CV, Weitz JI. Eikelboom JW, et al. J Am Coll Cardiol. 2019 Oct 8;74(14):1760-1768. doi: 10.1016/j.jacc.2019.07.070. J Am Coll Cardiol. 2019. PMID: 31582135